Psoriasis dating ireland

“The burden of living with psoriasis is often underestimated, and we want to help patients at all stages of their condition. With the brodalumab agreement, we are bringing a new option to many more people across the globe living with psoriasis.” Brodalumab received marketing authorization by the European Commission in July 2017 and is currently indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.[1] #ENDS# NOTE TO EDITORS About psoriasis An estimated 125 million people worldwide live with psoriasis.[2] It is a common, chronic, immune-mediated, inflammatory disease that primarily involves the skin.[3] The most frequently reported symptoms include thickening and scaling of the skin, itching and erythema (superficial reddening of the skin, usually in patches).[3] Psoriasis can be a painful, disabling and stigmatising condition with substantial social and psychological impact on a person’s life.[3]People with psoriasis, especially those with more severe symptoms, are also at increased risk of developing other serious associated conditions,[4] including heart disease[5],[6],[7] and metabolic diseases (a combination of diabetes, high blood pressure and obesity).[8] Mental health complications, such as depression and anxiety, are also more common in people with psoriasis.[9] According to the World Health Organization, the burden of living with psoriasis is underestimated and it urges for action to fight stigma and improve treatment.[3] About LEO Pharma LEO Pharma helps people achieve healthy skin. This may cause undue stress to someone living with psoriasis, and is completely based on false notions.

psoriasis dating ireland-8

With psoriasis, response to therapy may vary by person.

Some people will try several approaches until finding one that works well; others will try more than one therapy at a time.

Today people living with the disease and their advocates are working to highlight the facts about psoriasis and change the biases based on unfounded fears.

The European Union Clinical Trials Register allows you to search for protocol and results information on: Learn more about the EU Clinical Trials Register including the source of the information and the legal basis.

LEO Pharma is headquartered in Denmark with a global team of 5,500 people, serving 76 million patients in 130 countries.

In 2018, the company generated net sales of DKK 10,410 million.

This complements the ongoing licensing agreement between LEO Pharma A/S and Astra Zeneca to develop and market brodalumab for the treatment of moderate-to-severe psoriasis in Europe.

To date, LEO Pharma A/S has successfully launched brodalumab in 18 countries. through a licensing agreement with Astra Zeneca, has owned the global commercial rights for brodalumab except in Japan and other Asian countries, where the rights are owned by Kyowa Kirin Co., Ltd.

Diagnosis, understanding patients’ needs, appropriate treatment, and check-ins to see if the management plan should continue or be modified are key toward reaching the goals agreed upon by people with psoriasis and their health care teams. Some people see skin lesions and fear they will get the disease from being near a person with psoriasis or by touching their skin.

People with psoriasis are sometimes asked to leave public places like gyms or pools.

Psoriasis is a chronic immune mediated inflammatory disorder that affects approximately 2% of the world population or 140 million people worldwide.

Tags: , ,